Today, Novartis announced that the European Commission (EC) has approved Jakavi (ruxolitinib) for the treatment of patients with a rare blood cancer. The company said that the drug is now approved in Europe for the treatment of adults with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. …